PAVmed Subsidiary Veris Health Launches Commercial Phase of Strategic Partnership with Ohio State University Comprehensive Cancer Center

Reuters
Oct 07, 2025
PAVmed Subsidiary Veris Health Launches Commercial Phase of Strategic Partnership with Ohio State University Comprehensive Cancer Center

PAVmed Inc. and its subsidiary Veris Health have announced the launch of the commercial phase of their strategic partnership agreement with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). As part of this agreement, the Veris Cancer Care Platform will be deployed to enhance personalized cancer care for patients undergoing systemic cancer therapy at OSUCCC - James. The platform includes the VerisBox™ of connected health devices, a patient portal, and a clinician portal for remote monitoring and communication. Veris Health is also developing an implantable physiological monitor to further expand the platform's capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY91851) on October 07, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10